HeartFlow said today it won positive medical policies for its HeartFlow FFRct fractional flow reserve analysis system from 3 separate Blue Cross Blue Shield providers.
The Redwood City, Calif.-based company said that Anthem Blue Cross Blue Shield, Blue Shield of California and Blue Cross and Blue Shield of Alabama issued positive medical policies supporting the use of the FFRct technology following coronary computed tomography angiograms for members with stable chest pain.
The new positive decisions affect a total of 43 million individuals covered by the 3 companies, joining over 28.5 million individuals already covered by plans which have received positive policies for the FFRct tech, HeartFlow said.
“We are seeing increasing momentum in the number of national and regional commercial payors that are covering the HeartFlow FFRct Analysis for their members – based on the evidence demonstrating that it reduces the need for both non-invasive and invasive tests and procedures and lowers healthcare costs. With the growing number of health plans covering our technology, even more patients with suspected CAD will benefit by receiving a definitive personalized treatment plan based on the HeartFlow Analysis,” prez & CEO Dr. John Stevens said in a press release.
Earlier this week, HeartFlow said it inked a collaborative deal with Royal Philips (NYSE:PHG) to promote HeartFlow’s FFRct Analysis system along with Philips’ catheters for assessing coronary arteries in patients with suspected coronary artery disease.